MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: Relationship with type 2 diabetes complications

Fabiola Olivieri, Liana Spazzafumo, Massimiliano Bonafè, Rina Recchioni, Francesco Prattichizzo, Fiorella Marcheselli, Luigina Micolucci, Emanuela Mensà, Angelica Giuliani, Gabriele Santini, Mirko Gobbi, Raffaella Lazzarini, Massimo Boemi, Roberto Testa, Roberto Antonicelli, Antonio Domenico Procopio, Anna Rita Bonfigli

Research output: Contribution to journalArticle

Abstract

Innovative biomarkers are required to manage type 2 diabetic patients (T2DM). We focused our study on miR-126-3p and miR-21-5p levels, as biomarkers of endothelial function and inflammation. MiRNAs levels were measured in plasma from 107 healthy subjects (CTR) and 193 diabetic patients (T2DM), 76 without (T2DM NC) and 117 with (T2DM C) complications. When diabetic complication were analysed as a whole, miR-126-3p and miR- 21-5p levels declined significantly from CTR to T2DM NC and T2DM C patients. When miRNAs levels were related to specific complications, significantly higher miR-21- 5p levels (0.46 ± 0.44 vs. 0.26±0.33, p <0.001) and significant lower miR-126-3p levels (0.21±0.21 vs. 0.28±0.22, p = 0.032) were found in T2DM with previous major cardiovascular events (MACE) vs. all the others T2DM patients. To confirm these results we focused on circulating angiogenic cells (CACs) from a subgroup of 10 CTR, 15 T2DM NC and 15 T2DM patients with MACE. CACs from T2DM patients expressed higher miR-21-5p and lower miR-126-3p levels than CACs from CTR. Furthermore, CACs from T2DM + MACE showed the highest levels of miR-21-5p. Circulating miR-21-5p and miR-126-3p emerge as dynamic biomarkers of systemic inflammatory/angiogenic status. Their expression levels in CACs from T2DM with MACE suggest a shift from a proangiogenic to a proinflammatory profile.

Original languageEnglish
Pages (from-to)35372-35382
Number of pages11
JournalOncotarget
Volume6
Issue number34
DOIs
Publication statusPublished - 2015

Fingerprint

Diabetes Complications
Type 2 Diabetes Mellitus
Biomarkers
MicroRNAs
Healthy Volunteers
Inflammation

Keywords

  • Circulating miRNAs
  • Diabetes complication
  • Gerotarget
  • miR-126
  • miR-21
  • Type 2 diabetes

ASJC Scopus subject areas

  • Oncology

Cite this

MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells : Relationship with type 2 diabetes complications. / Olivieri, Fabiola; Spazzafumo, Liana; Bonafè, Massimiliano; Recchioni, Rina; Prattichizzo, Francesco; Marcheselli, Fiorella; Micolucci, Luigina; Mensà, Emanuela; Giuliani, Angelica; Santini, Gabriele; Gobbi, Mirko; Lazzarini, Raffaella; Boemi, Massimo; Testa, Roberto; Antonicelli, Roberto; Procopio, Antonio Domenico; Bonfigli, Anna Rita.

In: Oncotarget, Vol. 6, No. 34, 2015, p. 35372-35382.

Research output: Contribution to journalArticle

Olivieri, Fabiola ; Spazzafumo, Liana ; Bonafè, Massimiliano ; Recchioni, Rina ; Prattichizzo, Francesco ; Marcheselli, Fiorella ; Micolucci, Luigina ; Mensà, Emanuela ; Giuliani, Angelica ; Santini, Gabriele ; Gobbi, Mirko ; Lazzarini, Raffaella ; Boemi, Massimo ; Testa, Roberto ; Antonicelli, Roberto ; Procopio, Antonio Domenico ; Bonfigli, Anna Rita. / MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells : Relationship with type 2 diabetes complications. In: Oncotarget. 2015 ; Vol. 6, No. 34. pp. 35372-35382.
@article{4286fef80f5e4e49b3a74d7758b2caaa,
title = "MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: Relationship with type 2 diabetes complications",
abstract = "Innovative biomarkers are required to manage type 2 diabetic patients (T2DM). We focused our study on miR-126-3p and miR-21-5p levels, as biomarkers of endothelial function and inflammation. MiRNAs levels were measured in plasma from 107 healthy subjects (CTR) and 193 diabetic patients (T2DM), 76 without (T2DM NC) and 117 with (T2DM C) complications. When diabetic complication were analysed as a whole, miR-126-3p and miR- 21-5p levels declined significantly from CTR to T2DM NC and T2DM C patients. When miRNAs levels were related to specific complications, significantly higher miR-21- 5p levels (0.46 ± 0.44 vs. 0.26±0.33, p <0.001) and significant lower miR-126-3p levels (0.21±0.21 vs. 0.28±0.22, p = 0.032) were found in T2DM with previous major cardiovascular events (MACE) vs. all the others T2DM patients. To confirm these results we focused on circulating angiogenic cells (CACs) from a subgroup of 10 CTR, 15 T2DM NC and 15 T2DM patients with MACE. CACs from T2DM patients expressed higher miR-21-5p and lower miR-126-3p levels than CACs from CTR. Furthermore, CACs from T2DM + MACE showed the highest levels of miR-21-5p. Circulating miR-21-5p and miR-126-3p emerge as dynamic biomarkers of systemic inflammatory/angiogenic status. Their expression levels in CACs from T2DM with MACE suggest a shift from a proangiogenic to a proinflammatory profile.",
keywords = "Circulating miRNAs, Diabetes complication, Gerotarget, miR-126, miR-21, Type 2 diabetes",
author = "Fabiola Olivieri and Liana Spazzafumo and Massimiliano Bonaf{\`e} and Rina Recchioni and Francesco Prattichizzo and Fiorella Marcheselli and Luigina Micolucci and Emanuela Mens{\`a} and Angelica Giuliani and Gabriele Santini and Mirko Gobbi and Raffaella Lazzarini and Massimo Boemi and Roberto Testa and Roberto Antonicelli and Procopio, {Antonio Domenico} and Bonfigli, {Anna Rita}",
year = "2015",
doi = "10.18632/oncotarget.6164",
language = "English",
volume = "6",
pages = "35372--35382",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "34",

}

TY - JOUR

T1 - MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells

T2 - Relationship with type 2 diabetes complications

AU - Olivieri, Fabiola

AU - Spazzafumo, Liana

AU - Bonafè, Massimiliano

AU - Recchioni, Rina

AU - Prattichizzo, Francesco

AU - Marcheselli, Fiorella

AU - Micolucci, Luigina

AU - Mensà, Emanuela

AU - Giuliani, Angelica

AU - Santini, Gabriele

AU - Gobbi, Mirko

AU - Lazzarini, Raffaella

AU - Boemi, Massimo

AU - Testa, Roberto

AU - Antonicelli, Roberto

AU - Procopio, Antonio Domenico

AU - Bonfigli, Anna Rita

PY - 2015

Y1 - 2015

N2 - Innovative biomarkers are required to manage type 2 diabetic patients (T2DM). We focused our study on miR-126-3p and miR-21-5p levels, as biomarkers of endothelial function and inflammation. MiRNAs levels were measured in plasma from 107 healthy subjects (CTR) and 193 diabetic patients (T2DM), 76 without (T2DM NC) and 117 with (T2DM C) complications. When diabetic complication were analysed as a whole, miR-126-3p and miR- 21-5p levels declined significantly from CTR to T2DM NC and T2DM C patients. When miRNAs levels were related to specific complications, significantly higher miR-21- 5p levels (0.46 ± 0.44 vs. 0.26±0.33, p <0.001) and significant lower miR-126-3p levels (0.21±0.21 vs. 0.28±0.22, p = 0.032) were found in T2DM with previous major cardiovascular events (MACE) vs. all the others T2DM patients. To confirm these results we focused on circulating angiogenic cells (CACs) from a subgroup of 10 CTR, 15 T2DM NC and 15 T2DM patients with MACE. CACs from T2DM patients expressed higher miR-21-5p and lower miR-126-3p levels than CACs from CTR. Furthermore, CACs from T2DM + MACE showed the highest levels of miR-21-5p. Circulating miR-21-5p and miR-126-3p emerge as dynamic biomarkers of systemic inflammatory/angiogenic status. Their expression levels in CACs from T2DM with MACE suggest a shift from a proangiogenic to a proinflammatory profile.

AB - Innovative biomarkers are required to manage type 2 diabetic patients (T2DM). We focused our study on miR-126-3p and miR-21-5p levels, as biomarkers of endothelial function and inflammation. MiRNAs levels were measured in plasma from 107 healthy subjects (CTR) and 193 diabetic patients (T2DM), 76 without (T2DM NC) and 117 with (T2DM C) complications. When diabetic complication were analysed as a whole, miR-126-3p and miR- 21-5p levels declined significantly from CTR to T2DM NC and T2DM C patients. When miRNAs levels were related to specific complications, significantly higher miR-21- 5p levels (0.46 ± 0.44 vs. 0.26±0.33, p <0.001) and significant lower miR-126-3p levels (0.21±0.21 vs. 0.28±0.22, p = 0.032) were found in T2DM with previous major cardiovascular events (MACE) vs. all the others T2DM patients. To confirm these results we focused on circulating angiogenic cells (CACs) from a subgroup of 10 CTR, 15 T2DM NC and 15 T2DM patients with MACE. CACs from T2DM patients expressed higher miR-21-5p and lower miR-126-3p levels than CACs from CTR. Furthermore, CACs from T2DM + MACE showed the highest levels of miR-21-5p. Circulating miR-21-5p and miR-126-3p emerge as dynamic biomarkers of systemic inflammatory/angiogenic status. Their expression levels in CACs from T2DM with MACE suggest a shift from a proangiogenic to a proinflammatory profile.

KW - Circulating miRNAs

KW - Diabetes complication

KW - Gerotarget

KW - miR-126

KW - miR-21

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84946887838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946887838&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6164

DO - 10.18632/oncotarget.6164

M3 - Article

AN - SCOPUS:84946887838

VL - 6

SP - 35372

EP - 35382

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 34

ER -